Publicador de contenidos



Oral fexinidazole dosing regimens for the treatment of adults with chronic indeterminate Chagas disease

Foto: DNDi
04/10/2017 - 31/12/2018
Joaquim Gascon

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study

The general objective of this clinical trial is to determine the efficacy and safety of alternative dosing regimens of FEXI in reducing and clearing T. cruzi parasitemia in adult individuals with the chronic indeterminate Chagas Disease, in comparison to historical placebo control.

This is  a double-blind, randomized, prospective, comparative, pharmacokineticpharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control. The trial will be conducted in 5 different sites in Spain. The trial will be sufficiently powered to compare the efficacy and safety of each of the dosing regimens of FEXI with historical placebo control. Efficacy and safety will be monitored by an external independent Data Monitoring Committee (DMC) on an ongoing basis. The committee is to include cardiac and liver safety experts, as well as Chagas Disease clinical expertise.

The total duration of patient trial participation will be approximately 14 months.

Nuestro equipo


  • Joaquim Gascon Brustenga
    Joaquim Gascon Brustenga

ISGlobal team

Ver más

Otros proyectos

Ver proyectos pasados


Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Control of Leishmaniasis. From bench to bedside and community


Grup de recerca en patología importada i malaties emergents i re-emergents


Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas


Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults


Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas


MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention


Citizens engagement digital platform for collective intelligence in pandemics


Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria


Building Scalable Pathogen Genomic Epidemiology in Ethiopia


Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test


Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses


P. falciparum genomic intelligence in Mozambique


Broad One Health Endectocide-based Malaria Intervention in Africa


Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum


Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria


Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria


Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.


Social affairs and sex in P. falciparum: implications for malaria elimination

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy


La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.